Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • mtdsus mtdsus Oct 19, 2012 12:21 PM Flag

    NASH-Liver disease affects 2-5% of Americans -Reason for Epadel phase 2 trials.

    Vascepa some day--could be used for Liver disease--NASH-- if Epadel's Phase 2 trials are significant.
    Currently no drug has been identified if you read National Digestive Disease Information on Steato-Hepatitis.
    POTENTIAL SALES is HUGE.
    I do not think Amarin knows.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Mochida which sold Epadel(90% pure EPA) in Japan is trying to extend Epadel use in other big area.There are 7-20 million who suffer from this Liver disease-silently.
      It will be interesting to watch phase 2 trials for Epadel in Japan.

 
AMRN
2.34-0.05(-2.09%)Mar 31 4:00 PMEDT